Neuroprotection and axon regeneration therapies for CNS axonopathies by modulating mitochondria trafficking

Stanford researchers have developed a new therapeutic approach to protect neurons and promote axon regeneration by restoring mitochondrial transport within axons, a key process disrupted in many neurodegenerative diseases.

Axon degeneration is an early and common feature of central nervous system (CNS) disorders such as glaucoma and amyotrophic lateral sclerosis (ALS). In adult CNS neurons, damaged axons have a very limited ability to regenerate, leading to irreversible loss of function. Current treatments primarily manage symptoms and do not address the underlying causes of neuronal degeneration.

This approach is based on the discovery that the protein optineurin (OPTN) plays a critical role in maintaining axonal health by stabilizing the mitochondrial transport machinery. Disruption of this process leads to reduced mitochondrial distribution in axons and precedes neuronal degeneration. The researchers demonstrated that enhancing this pathway by increasing the levels or activity of OPTN and related proteins can restore mitochondrial movement, improve neuronal survival, and promote axon regeneration in disease and injury models.

By directly targeting a fundamental mechanism of axonal degeneration, this approach offers a potential path toward disease-modifying and regenerative therapies for CNS neurodegenerative diseases.